McMahon M, Marsh H M, Rizza R A
Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905.
Diabetes. 1989 Mar;38(3):291-303. doi: 10.2337/diab.38.3.291.
Basal insulin supplementation has been used as a therapy for patients with non-insulin-dependent diabetes mellitus (NIDDM) who require insulin. To determine whether basal insulin supplementation in addition to lowering postabsorptive plasma glucose concentration also improves the postprandial pattern of glucose disposition, glucose metabolism after ingestion of a solid mixed meal was assessed in obese patients with NIDDM before and after treatment with ultralente and compared with glucose metabolism observed in nondiabetic subjects. Splanchnic uptake of ingested glucose clearance was assessed by including [2-3H]glucose (a tracer that only minimally cycles through glycogen) in a solid mixed meal. Postprandial gluconeogenesis was estimated by measuring the rate of incorporation of carbon dioxide into glucose. Net glucose and lipid oxidation were measured by indirect calorimetry. Both splanchnic uptake of ingested glucose (27 +/- 1 vs. 14 +/- 2 g) and postprandial hepatic glucose release (51 +/- 5 vs. 24 +/- 3 g) were greater (P less than .001) in diabetic than in nondiabetic subjects. Although the percentage of postprandial hepatic glucose release accounted for by glucose synthesis from bicarbonate was similar in the two groups (25 +/- 2 vs. 35 +/- 5%), the absolute rate was greater in the diabetic patients (13 +/- 1 vs. 8 +/- 1 g; P less than .05). Postprandial glucose oxidation and glucose disposal (measured either isotopically or by the forearm-catheterization technique) were similar in both groups. However, total lipid oxidation was increased in the diabetic patients. (P less than .05). Two weeks of basal insulin supplementation lowered fasting glucose concentrations (from 219 +/- 22 to 144 +/- 21 mg/dl; P less than .01) and integrated postprandial glycemic response (from 814 +/- 68 to 621 +/- 72 min.mg.ml-1) but not to normal. Although circulating insulin concentrations were two- to threefold greater (P less than .02) after 3 mo of basal insulin supplementation, the postprandial pattern of glucose metabolism remained essentially the same. Basal insulin supplementation decreased (P less than .05) both splanchnic uptake of ingested glucose and hepatic glucose release. The addition of a preprandial injection of soluble insulin to basal insulin supplementation further suppressed (P less than .05) postprandial hepatic glucose release, thereby further improving postprandial glucose tolerance. These studies indicate that initial splanchnic glucose clearance, hepatic glucose release, and new glucose synthesis, as well as extrahepatic substrate metabolism, are altered in NIDDM after ingestion of a mixed meal.(ABSTRACT TRUNCATED AT 400 WORDS)
基础胰岛素补充疗法已被用于治疗需要胰岛素的非胰岛素依赖型糖尿病(NIDDM)患者。为了确定基础胰岛素补充疗法除了能降低吸收后血浆葡萄糖浓度外,是否还能改善餐后葡萄糖处置模式,我们评估了肥胖NIDDM患者在接受超长效胰岛素治疗前后,摄入固体混合餐后的葡萄糖代谢情况,并与非糖尿病受试者的葡萄糖代谢情况进行了比较。通过在固体混合餐中加入[2-³H]葡萄糖(一种仅少量循环通过糖原的示踪剂)来评估内脏对摄入葡萄糖的摄取清除情况。通过测量二氧化碳掺入葡萄糖的速率来估计餐后糖异生情况。通过间接测热法测量净葡萄糖和脂质氧化情况。糖尿病患者摄入葡萄糖的内脏摄取量(27±1克对14±2克)和餐后肝脏葡萄糖释放量(51±5克对24±3克)均高于非糖尿病受试者(P<0.001)。尽管两组中由碳酸氢盐合成葡萄糖所占的餐后肝脏葡萄糖释放百分比相似(25±2%对35±5%),但糖尿病患者的绝对速率更高(13±1克对8±1克;P<0.05)。两组餐后葡萄糖氧化和葡萄糖处置(通过同位素或前臂插管技术测量)相似。然而,糖尿病患者的总脂质氧化增加(P<0.05)。两周的基础胰岛素补充疗法降低了空腹血糖浓度(从219±22毫克/分升降至144±21毫克/分升;P<0.01)以及餐后血糖综合反应(从814±68降至621±72分钟·毫克·毫升⁻¹),但未恢复至正常水平。尽管基础胰岛素补充治疗3个月后循环胰岛素浓度增加了两到三倍(P<0.02),但餐后葡萄糖代谢模式基本保持不变。基础胰岛素补充疗法降低了(P<0.05)摄入葡萄糖的内脏摄取量和肝脏葡萄糖释放量。在基础胰岛素补充疗法基础上餐前注射可溶性胰岛素进一步抑制了(P<0.05)餐后肝脏葡萄糖释放,从而进一步改善了餐后葡萄糖耐量。这些研究表明,摄入混合餐后,NIDDM患者最初的内脏葡萄糖清除、肝脏葡萄糖释放、新葡萄糖合成以及肝外底物代谢均发生了改变。(摘要截选至400字)